Literature DB >> 22487487

Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?

Yishan Liu1, Ljiljana Vlatkovic, Thorstein Sæter, Einar Servoll, Gudmund Waaler, Jahn M Nesland, Karl-Erik Giercksky, Karol Axcrona.   

Abstract

OBJECTIVES: To assess the expression of the cell surface protein B7-H3 in prostate cancer, and its association to clinically relevant parameters after radical prostatectomy and to the proliferation marker Ki-67.
METHODS: Radical prostatectomy specimens from a cohort of 130 patients with a median clinical follow up of 8 years were used for the analysis. The expression of B7-H3 and the proliferation marker Ki-67, as well as other standard clinicopathological parameters, were evaluated.
RESULTS: A high expression of B7-H3 was associated with pathological stage T3a and T3b, high Gleason score, extraprostatic extension, seminal vesicle invasion and high proliferative activity. Univariable analysis showed that a high expression level of B7-H3 was also correlated with biochemical failure and clinical relapse, and with the expression of Ki-67. A high expression level of Ki-67 was associated with clinical progression and a tendency towards higher rates of prostate-specific antigen relapse in multivariate analyses.
CONCLUSIONS: Our findings show that a high expression level of B7-H3 in prostate cancer correlates with the expression of the proliferation marker Ki-67, biochemical failure and clinical relapse. Thus, expression of the cell surface molecule B7-H3 adds to the malignant phenotype of prostate cancer cells expressing high levels of Ki-67. The impact of B7-H3 function on prostate cancer and its potential role in immunotherapy should be explored further.
© 2012 The Japanese Urological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22487487     DOI: 10.1111/j.1442-2042.2012.03017.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  13 in total

Review 1.  Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.

Authors:  Angela K B Alme; Beerinder S Karir; Bishoy M Faltas; Charles G Drake
Journal:  Urol Oncol       Date:  2016-02-28       Impact factor: 3.498

2.  Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.

Authors:  Teresa Di Desidero; Lisa Derosa; Luca Galli; Paola Orlandi; Andrea Fontana; Anna Fioravanti; Riccardo Marconcini; Mario Giorgi; Beatrice Campi; Alessandro Saba; Sara Lucchesi; Renato Felipetto; Romano Danesi; Giulio Francia; Giacomo Allegrini; Alfredo Falcone; Guido Bocci
Journal:  Invest New Drugs       Date:  2016-08-24       Impact factor: 3.850

3.  Overexpression of B7-H3 in CD14+ monocytes is associated with renal cell carcinoma progression.

Authors:  Miao Li; Guangbo Zhang; Xuefeng Zhang; Guanglin Lv; Xuedong Wei; Hexing Yuan; Jianquan Hou
Journal:  Med Oncol       Date:  2014-11-22       Impact factor: 3.064

4.  Promoter Methylation Analysis Reveals That KCNA5 Ion Channel Silencing Supports Ewing Sarcoma Cell Proliferation.

Authors:  Katherine E Ryland; Allegra G Hawkins; Daniel J Weisenberger; Vasu Punj; Scott C Borinstein; Peter W Laird; Jeffrey R Martens; Elizabeth R Lawlor
Journal:  Mol Cancer Res       Date:  2015-11-16       Impact factor: 5.852

5.  Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.

Authors:  Gulanbar Amori; Emiko Sugawara; Yasuyuki Shigematsu; Masashi Akiya; Junko Kunieda; Takeshi Yuasa; Shinya Yamamoto; Junji Yonese; Kengo Takeuchi; Kentaro Inamura
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-02-08       Impact factor: 5.554

6.  B7-H3 targeted antibody-based immunotherapy of malignant diseases.

Authors:  Theodoros Michelakos; Filippos Kontos; Omar Barakat; Luke Maggs; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Expert Opin Biol Ther       Date:  2020-12-21       Impact factor: 4.388

Review 7.  Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?

Authors:  Alessandra Modena; Chiara Ciccarese; Roberto Iacovelli; Matteo Brunelli; Rodolfo Montironi; Michelangelo Fiorentino; Giampaolo Tortora; Francesco Massari
Journal:  Oncol Rev       Date:  2016-04-15

Review 8.  Current status of biomarkers for prostate cancer.

Authors:  Vicki M Velonas; Henry H Woo; Cristobal G dos Remedios; Stephen J Assinder
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

9.  The co-stimulatory molecule B7-H3 promotes the epithelial-mesenchymal transition in colorectal cancer.

Authors:  Bo Jiang; Ting Zhang; Fen Liu; Zhangzhang Sun; Hanping Shi; Dong Hua; Chen Yang
Journal:  Oncotarget       Date:  2016-05-31

Review 10.  Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?

Authors:  Dong Lin; Xinya Wang; Stephen Yiu Chuen Choi; Xinpei Ci; Xin Dong; Yuzhuo Wang
Journal:  Asian J Urol       Date:  2016-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.